APLAR rheumatoid arthritis treatment recommendations
Aims Rheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines and recommendations available to support the treatment of rheumatoid arthritis; however, the evidence used for these guidelines is predomi...
Saved in:
| Published in | International journal of rheumatic diseases Vol. 18; no. 7; pp. 685 - 713 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article Conference Proceeding |
| Language | English |
| Published |
England
Blackwell Publishing Ltd
01.09.2015
Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1756-1841 1756-185X |
| DOI | 10.1111/1756-185X.12754 |
Cover
Loading…
| Abstract | Aims
Rheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines and recommendations available to support the treatment of rheumatoid arthritis; however, the evidence used for these guidelines is predominantly based on studies in Caucasian subjects and may not be relevant for rheumatoid arthritis patients in the Asia‐Pacific region. Therefore, the Asia Pacific League of Associations for Rheumatology established a Steering Committee in 2013 to address this issue.
Materials and methods
The AGREE II instrument and the ADAPTE Collaboration framework were applied to systematically identify, appraise, synthesize, and adapt international rheumatoid arthritis guidelines for use in the Asia‐Pacific region.
Results
Forty rheumatoid arthritis treatment recommendations, based on evidence and expert opinion, were drafted and are presented in this report.
Conclusion
The Asia Pacific of Associations for Rheumatology rheumatoid arthritis treatment recommendations are intended to serve as a reference for best practice management of rheumatoid arthritis in Asia‐Pacific, focusing on local issues to ensure the delivery of basic care for these patients, and to improve their outcomes. In addition, the document will serve as a reference for national rheumatology associations in Asia‐Pacific for developing guidelines in their respective countries. |
|---|---|
| AbstractList | AIMSRheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines and recommendations available to support the treatment of rheumatoid arthritis; however, the evidence used for these guidelines is predominantly based on studies in Caucasian subjects and may not be relevant for rheumatoid arthritis patients in the Asia-Pacific region. Therefore, the Asia Pacific League of Associations for Rheumatology established a Steering Committee in 2013 to address this issue.MATERIALS AND METHODSThe AGREE II instrument and the ADAPTE Collaboration framework were applied to systematically identify, appraise, synthesize, and adapt international rheumatoid arthritis guidelines for use in the Asia-Pacific region.RESULTSForty rheumatoid arthritis treatment recommendations, based on evidence and expert opinion, were drafted and are presented in this report.CONCLUSIONThe Asia Pacific of Associations for Rheumatology rheumatoid arthritis treatment recommendations are intended to serve as a reference for best practice management of rheumatoid arthritis in Asia-Pacific, focusing on local issues to ensure the delivery of basic care for these patients, and to improve their outcomes. In addition, the document will serve as a reference for national rheumatology associations in Asia-Pacific for developing guidelines in their respective countries. Aims Rheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines and recommendations available to support the treatment of rheumatoid arthritis; however, the evidence used for these guidelines is predominantly based on studies in Caucasian subjects and may not be relevant for rheumatoid arthritis patients in the Asia-Pacific region. Therefore, the Asia Pacific League of Associations for Rheumatology established a Steering Committee in 2013 to address this issue. Materials and methods The AGREE II instrument and the ADAPTE Collaboration framework were applied to systematically identify, appraise, synthesize, and adapt international rheumatoid arthritis guidelines for use in the Asia-Pacific region. Results Forty rheumatoid arthritis treatment recommendations, based on evidence and expert opinion, were drafted and are presented in this report. Conclusion The Asia Pacific of Associations for Rheumatology rheumatoid arthritis treatment recommendations are intended to serve as a reference for best practice management of rheumatoid arthritis in Asia-Pacific, focusing on local issues to ensure the delivery of basic care for these patients, and to improve their outcomes. In addition, the document will serve as a reference for national rheumatology associations in Asia-Pacific for developing guidelines in their respective countries. Rheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines and recommendations available to support the treatment of rheumatoid arthritis; however, the evidence used for these guidelines is predominantly based on studies in Caucasian subjects and may not be relevant for rheumatoid arthritis patients in the Asia-Pacific region. Therefore, the Asia Pacific League of Associations for Rheumatology established a Steering Committee in 2013 to address this issue. The AGREE II instrument and the ADAPTE Collaboration framework were applied to systematically identify, appraise, synthesize, and adapt international rheumatoid arthritis guidelines for use in the Asia-Pacific region. Forty rheumatoid arthritis treatment recommendations, based on evidence and expert opinion, were drafted and are presented in this report. The Asia Pacific of Associations for Rheumatology rheumatoid arthritis treatment recommendations are intended to serve as a reference for best practice management of rheumatoid arthritis in Asia-Pacific, focusing on local issues to ensure the delivery of basic care for these patients, and to improve their outcomes. In addition, the document will serve as a reference for national rheumatology associations in Asia-Pacific for developing guidelines in their respective countries. Aims Rheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines and recommendations available to support the treatment of rheumatoid arthritis; however, the evidence used for these guidelines is predominantly based on studies in Caucasian subjects and may not be relevant for rheumatoid arthritis patients in the Asia‐Pacific region. Therefore, the Asia Pacific League of Associations for Rheumatology established a Steering Committee in 2013 to address this issue. Materials and methods The AGREE II instrument and the ADAPTE Collaboration framework were applied to systematically identify, appraise, synthesize, and adapt international rheumatoid arthritis guidelines for use in the Asia‐Pacific region. Results Forty rheumatoid arthritis treatment recommendations, based on evidence and expert opinion, were drafted and are presented in this report. Conclusion The Asia Pacific of Associations for Rheumatology rheumatoid arthritis treatment recommendations are intended to serve as a reference for best practice management of rheumatoid arthritis in Asia‐Pacific, focusing on local issues to ensure the delivery of basic care for these patients, and to improve their outcomes. In addition, the document will serve as a reference for national rheumatology associations in Asia‐Pacific for developing guidelines in their respective countries. |
| Author | Jain, Rahul Harrison, Andrew Suryana, Bagus Putu Putra Luo, Shue-Fen Lichauco, Juan Javier Lau, Chak Sing Leong, Khai Pang Park, Sung-Hwan Suwannalai, Parawee Hsieh, Tsu-Yi Jung, Seung Min Kumar, Ashok Nash, Peter Yamamoto, Kazuhiko Ng, Chin Teck Li, Zhanguo Yeap, Swan Sim Wijaya, Linda Kurniaty Louthrenoo, Worawit Chia, Faith Kishimoto, Mitsumasa Yang, Yue |
| Author_xml | – sequence: 1 givenname: Chak Sing surname: Lau fullname: Lau, Chak Sing email: cslau@hku.hk organization: Division of Rheumatology and Clinical Immunology, Queen Mary Hospital, University of Hong Kong, Hong Kong – sequence: 2 givenname: Faith surname: Chia fullname: Chia, Faith organization: Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore City, Singapore – sequence: 3 givenname: Andrew surname: Harrison fullname: Harrison, Andrew organization: Department of Medicine, University of Otago Wellington, Wellington South, New Zealand – sequence: 4 givenname: Tsu-Yi surname: Hsieh fullname: Hsieh, Tsu-Yi organization: Section of Allergy, Immunology and Rheumatology, and Section of Clinical Skills Training, Taichung Veterans General Hospital, Taichung, Taiwan – sequence: 5 givenname: Rahul surname: Jain fullname: Jain, Rahul organization: Narayana Hospital, Jaipur, India – sequence: 6 givenname: Seung Min surname: Jung fullname: Jung, Seung Min organization: Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea, St. Mary's Hospital, Seoul, South Korea – sequence: 7 givenname: Mitsumasa surname: Kishimoto fullname: Kishimoto, Mitsumasa organization: Immuno-Rheumatology Center, St Luke's International Hospital, Tokyo, Japan – sequence: 8 givenname: Ashok surname: Kumar fullname: Kumar, Ashok organization: Department of Rheumatology, Fortis Flt. Lt Rajan Dhall Hospital, New Delhi, India – sequence: 9 givenname: Khai Pang surname: Leong fullname: Leong, Khai Pang organization: Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore City, Singapore – sequence: 10 givenname: Zhanguo surname: Li fullname: Li, Zhanguo organization: Department of Rheumatology, Peking University People's Hospital, Beijing, China – sequence: 11 givenname: Juan Javier surname: Lichauco fullname: Lichauco, Juan Javier organization: St. Luke's Medical Center, Quezon City, Philippines – sequence: 12 givenname: Worawit surname: Louthrenoo fullname: Louthrenoo, Worawit organization: Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand – sequence: 13 givenname: Shue-Fen surname: Luo fullname: Luo, Shue-Fen organization: Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan – sequence: 14 givenname: Peter surname: Nash fullname: Nash, Peter organization: Department of Medicine, University of Queensland, Queensland, Brisbane, Australia – sequence: 15 givenname: Chin Teck surname: Ng fullname: Ng, Chin Teck organization: Department of Rheumatology and Immunology, Singapore General Hospital, Singapore City, Singapore – sequence: 16 givenname: Sung-Hwan surname: Park fullname: Park, Sung-Hwan organization: Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea, St. Mary's Hospital, Seoul, South Korea – sequence: 17 givenname: Bagus Putu Putra surname: Suryana fullname: Suryana, Bagus Putu Putra organization: Rheumatology Division, Department of Internal Medicine, Brawijaya University, Saiful Anwar General Hospital, Malang, Indonesia – sequence: 18 givenname: Parawee surname: Suwannalai fullname: Suwannalai, Parawee organization: Allergy, Immunology and Rheumatology Division, Internal Medicine Department, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand – sequence: 19 givenname: Linda Kurniaty surname: Wijaya fullname: Wijaya, Linda Kurniaty organization: Division of Rheumatology, Department of Internal Medicine, University of Indonesia, Jakarta, Indonesia – sequence: 20 givenname: Kazuhiko surname: Yamamoto fullname: Yamamoto, Kazuhiko organization: Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan – sequence: 21 givenname: Yue surname: Yang fullname: Yang, Yue organization: Department of Rheumatology, Peking University People's Hospital, Beijing, China – sequence: 22 givenname: Swan Sim surname: Yeap fullname: Yeap, Swan Sim organization: Subang Jaya Medical Centre, Selangor, Malaysia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26334449$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkctLAzEQxoMoaqtnb1Lw4mU12bzcYylahaLiA3sLMTvB6D40yaL-96bPgyDmMpPh901mvvTQZtM2gNABwScknVMiucjIGZ-ekFxytoF215XNdc7IDuqF8IqxIFTIbbSTC0oZY8UuYsPbyfBu4F-gq3VsXTnQPr54F10YRA861tDEgQfT1ikrdXRtE_bQltVVgP1l7KPHi_OH0WU2uRlfjYaTzHAiWEZzYsFahgnGmhVSyNKkAcp0oaLQTDObS20ZGCgkMMD2WRvNpRWGlEVe0j46XvR99-1HByGq2gUDVaUbaLugiMSFxIIzltCjX-hr2_kmTTenmOBFWr6PDpdU91xDqd69q7X_Vis_EsAXgPFtCB6sMi7Ol45eu0oRrGa-q5mzauaymvuedKe_dKvWfyuWL326Cr7_w1X6ppUuW-hciPC11mn_poSkkqun67Eq8P2UTka5uqQ_hZ6g3A |
| CitedBy_id | crossref_primary_10_1007_s12325_021_01867_8 crossref_primary_10_1007_s10067_019_04761_5 crossref_primary_10_1093_rheumatology_kez224 crossref_primary_10_1016_j_berh_2024_102019 crossref_primary_10_1007_s00296_021_04994_1 crossref_primary_10_1111_1756_185X_13748 crossref_primary_10_52547_jccs_2_3_103 crossref_primary_10_1136_rmdopen_2016_000382 crossref_primary_10_19161_etd_864145 crossref_primary_10_1136_bmjopen_2024_097715 crossref_primary_10_1136_annrheumdis_2016_210715 crossref_primary_10_2478_rir_2021_0002 crossref_primary_10_1007_s00296_017_3749_7 crossref_primary_10_1080_14397595_2018_1553489 crossref_primary_10_1136_annrheumdis_2018_214918 crossref_primary_10_1371_journal_pone_0205651 crossref_primary_10_2478_rir_2022_0010 crossref_primary_10_1021_acsnano_9b01710 crossref_primary_10_1016_j_biomaterials_2024_122839 crossref_primary_10_1111_1756_185X_13692 crossref_primary_10_1177_1203475420914622 crossref_primary_10_37667_pk_2017_1016 crossref_primary_10_1111_1756_185X_13853 crossref_primary_10_1007_s40674_021_00172_3 crossref_primary_10_3390_medicina58050571 crossref_primary_10_1007_s10067_019_04721_z crossref_primary_10_3390_jcm8040515 crossref_primary_10_1007_s10067_023_06782_7 crossref_primary_10_1007_s00296_018_4096_z crossref_primary_10_1155_2018_9806160 crossref_primary_10_1002_cbin_10861 crossref_primary_10_37990_medr_1269997 crossref_primary_10_1111_1756_185X_13129 crossref_primary_10_1002_acr_23185 crossref_primary_10_1002_msc_1404 crossref_primary_10_19161_etd_863635 crossref_primary_10_1186_s13018_021_02603_2 crossref_primary_10_1142_S2661341721300056 crossref_primary_10_1111_1756_185X_13762 crossref_primary_10_1007_s00296_017_3780_8 crossref_primary_10_1590_1678_4324_2022220151 crossref_primary_10_1007_s10067_017_3725_3 crossref_primary_10_4103_0366_6999_245157 crossref_primary_10_3389_fimmu_2023_1150661 crossref_primary_10_1111_1756_185X_13516 crossref_primary_10_1177_0706743717719897 crossref_primary_10_1007_s10067_019_04894_7 crossref_primary_10_1111_1756_185X_13238 crossref_primary_10_1111_1756_185X_13513 crossref_primary_10_12677_ACM_2021_1111736 crossref_primary_10_1016_j_reuma_2018_06_007 crossref_primary_10_3389_fendo_2019_00729 crossref_primary_10_3389_fphar_2021_628548 crossref_primary_10_1097_MOO_0000000000000312 crossref_primary_10_1016_j_biopha_2019_109704 crossref_primary_10_1038_s41413_019_0067_6 crossref_primary_10_1007_s10067_021_05811_7 crossref_primary_10_1136_annrheumdis_2017_211455 crossref_primary_10_1007_s40744_018_0118_2 crossref_primary_10_1016_j_gastre_2020_04_006 crossref_primary_10_1186_s42358_021_00205_4 crossref_primary_10_1002_14651858_CD014898 crossref_primary_10_1002_tox_23529 crossref_primary_10_1007_s12325_021_01733_7 crossref_primary_10_3899_jrheum_170486 crossref_primary_10_1007_s00296_018_3996_2 crossref_primary_10_1080_14712598_2019_1645114 crossref_primary_10_1093_rheumatology_keac472 crossref_primary_10_1016_j_berh_2016_08_007 crossref_primary_10_14412_1995_4484_2020_62_79 crossref_primary_10_2139_ssrn_4045944 crossref_primary_10_1002_jcp_27860 crossref_primary_10_1111_1756_185X_15319 crossref_primary_10_1016_j_arth_2020_06_085 crossref_primary_10_1186_s41927_019_0090_7 crossref_primary_10_1186_s13075_019_1937_4 crossref_primary_10_4078_jrd_2020_27_1_4 crossref_primary_10_1371_journal_pone_0235637 crossref_primary_10_1515_hkbrd_2017_0009 crossref_primary_10_1007_s10067_023_06654_0 crossref_primary_10_1136_ard_2022_222784 crossref_primary_10_1002_acr_23865 crossref_primary_10_1007_s10067_021_05876_4 crossref_primary_10_1111_1756_185X_14185 crossref_primary_10_1016_j_phrs_2022_106405 crossref_primary_10_1111_1756_185X_13130 crossref_primary_10_1007_s40265_020_01256_5 crossref_primary_10_3346_jkms_2021_36_e109 crossref_primary_10_4236_jbm_2017_59002 crossref_primary_10_3904_kjim_2019_411 crossref_primary_10_1080_14397595_2021_1892945 crossref_primary_10_3389_fbioe_2020_00872 crossref_primary_10_1136_annrheumdis_2019_216655 crossref_primary_10_2217_imt_2018_0113 crossref_primary_10_2217_imt_2017_0118 crossref_primary_10_1038_nrdp_2018_1 crossref_primary_10_1016_j_carbpol_2022_119183 crossref_primary_10_1080_13696998_2019_1606813 crossref_primary_10_1016_j_rdc_2019_07_001 crossref_primary_10_1371_journal_pone_0226754 crossref_primary_10_1002_jcla_22862 crossref_primary_10_1016_j_reumae_2018_06_004 crossref_primary_10_1007_s10067_020_05054_y crossref_primary_10_1016_j_gastrohep_2020_04_006 |
| Cites_doi | 10.3109/s10165-004-0357-7 10.1136/ard.2009.127225 10.1002/art.21519 10.3109/14397595.2013.854074 10.1016/j.jbspin.2004.10.011 10.1002/art.20217 10.3899/jrheum.110207 10.1002/art.24643 10.1136/bmj.h1046 10.1093/rheumatology/keq316 10.1136/qhc.12.1.18 10.1136/ard.2009.126532 10.1056/NEJMra1004965 10.3899/jrheum.120165 10.1093/rheumatology/keh464 10.1016/S1297-319X(02)00387-1 10.1056/NEJMoa1109071 10.1016/S0140-6736(07)60784-3 10.1056/NEJM200011303432202 10.1002/acr.21641 10.1007/s10067-010-1596-y 10.1093/rheumatology/keq006a 10.1136/ard.62.8.791 10.1016/S0140-6736(12)60027-0 10.1371/journal.pone.0048991 10.1136/ard.2008.094474 10.1186/ar1736 10.1002/art.30310 10.1016/j.jbspin.2009.12.011 10.1002/art.21734 10.1136/annrheumdis-2012-202469 10.1136/ard.2010.140822 10.1136/annrheumdis-2013-204906 10.1016/S1470-2045(09)70265-7 10.1002/art.23721 10.3109/s10165-005-0466-y 10.1016/j.autrev.2014.12.011 10.1136/bmj.323.7308.334 10.1001/jama.295.19.2275 10.1054/bjoc.2001.1872 10.3109/s10165-011-0425-8 10.1016/j.reuma.2011.07.002 10.1136/ard.2009.123919 10.1136/ard.2008.099861 10.1056/NEJMoa1112072 10.1093/rheumatology/keq399 10.1016/S0973-3698(10)60373-1 10.1186/1477-7525-7-25 10.1016/j.jbspin.2006.04.001 10.1002/art.10697 10.1136/annrheumdis-2013-204573 10.1016/j.jbspin.2007.10.001 10.1093/rheumatology/38.7.668 10.3109/s10165-009-0197-6 10.1093/rheumatology/ken450a 10.1016/S0140-6736(12)61424-X 10.3109/s10165-007-0626-3 10.1093/rheumatology/keh554 10.1016/j.autrev.2008.05.001 10.1056/NEJMoa1303006 10.1038/ncprheum0509 10.3109/s10165-006-0457-7 10.1002/art.23281 10.1136/thx.2005.046797 10.1002/art.34498 10.1136/ard.2009.127332 10.1002/art.37816 10.1002/msc.171 10.1093/rheumatology/40.6.699 10.1016/j.jbspin.2004.10.010 10.3109/s10165-006-0542-y 10.1002/ijc.23741 10.1590/S0482-50042012000200002 10.1136/ard.2006.062760 10.1136/ard.2010.144998 10.1053/j.semarthrit.2003.10.003 10.1136/ard.2009.126748 10.1002/art.10524 10.1161/01.CIR.0000077913.60364.D2 10.1136/ard.2006.061002 10.1111/j.1479-8077.2006.00182.x 10.7326/0003-4819-159-4-201308200-00006 10.1093/rheumatology/ker106a 10.1136/ard.2005.044354 10.1136/ard.61.4.290 10.1093/rheumatology/kel215a 10.1503/cmaj.090449 10.1136/ard.2008.094904 10.3899/jrheum.090978 10.1007/s00296-013-2848-3 |
| ContentType | Journal Article Conference Proceeding |
| Copyright | 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd. International Journal of Rheumatic Diseases © 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd |
| Copyright_xml | – notice: 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd – notice: 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd. – notice: International Journal of Rheumatic Diseases © 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd |
| CorporateAuthor | Asia Pacific League of Associations for Rheumatology |
| CorporateAuthor_xml | – name: Asia Pacific League of Associations for Rheumatology |
| DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7T5 H94 7X8 |
| DOI | 10.1111/1756-185X.12754 |
| DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Calcium & Calcified Tissue Abstracts Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1756-185X |
| EndPage | 713 |
| ExternalDocumentID | 3797552761 26334449 10_1111_1756_185X_12754 APL12754 ark_67375_WNG_90SX3LC2_H |
| Genre | reviewArticle Review Consensus Development Conference Research Support, Non-U.S. Gov't Journal Article Practice Guideline |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OC 29J 31~ 33P 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZFZN BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBD EBS EJD EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA HF~ HGLYW HVGLF HZI HZ~ IX1 K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR XG1 ~IA ~WT AAHQN AAIPD AAMMB AAMNL AANHP AAYCA ACRPL ACUHS ACYXJ ADNMO AEFGJ AFWVQ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY ALVPJ AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7T5 H94 7X8 |
| ID | FETCH-LOGICAL-c5164-321feff40100a49767dc136d0a4369a4a4f27af4ece97e4e0fbaca57f6c1d92d3 |
| IEDL.DBID | DR2 |
| ISSN | 1756-1841 |
| IngestDate | Thu Jul 10 18:57:37 EDT 2025 Fri Jul 25 02:45:48 EDT 2025 Thu Apr 03 07:06:13 EDT 2025 Tue Jul 01 03:31:13 EDT 2025 Thu Apr 24 22:52:42 EDT 2025 Wed Aug 20 07:25:08 EDT 2025 Wed Oct 30 09:52:10 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | rheumatoid arthritis drug treatment |
| Language | English |
| License | 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5164-321feff40100a49767dc136d0a4369a4a4f27af4ece97e4e0fbaca57f6c1d92d3 |
| Notes | istex:5FCED676357572D2A61A6EE14299E0E08030FF21 ArticleID:APL12754 ark:/67375/WNG-90SX3LC2-H ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Instructional Material/Guideline-6 ObjectType-News-1 ObjectType-Review-3 ObjectType-Conference-2 SourceType-Conference Papers & Proceedings-1 ObjectType-Feature-5 content type line 25 ObjectType-Article-4 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1756-185X.12754 |
| PMID | 26334449 |
| PQID | 1709465961 |
| PQPubID | 1086355 |
| PageCount | 29 |
| ParticipantIDs | proquest_miscellaneous_1709706544 proquest_journals_1709465961 pubmed_primary_26334449 crossref_citationtrail_10_1111_1756_185X_12754 crossref_primary_10_1111_1756_185X_12754 wiley_primary_10_1111_1756_185X_12754_APL12754 istex_primary_ark_67375_WNG_90SX3LC2_H |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2015-09 September 2015 2015-09-00 2015-Sep 20150901 |
| PublicationDateYYYYMMDD | 2015-09-01 |
| PublicationDate_xml | – month: 09 year: 2015 text: 2015-09 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Richmond |
| PublicationTitle | International journal of rheumatic diseases |
| PublicationTitleAlternate | Int J Rheum Dis |
| PublicationYear | 2015 |
| Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc |
| References | Fleischmann R, Kremer J, Cush J et al. (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367, 495-507. Gossec L, Fautrel B, Pham T et al. (2005) Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 72, 229-34. Caporali R, Conti F, Alivernini S et al. (2011) Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol 29 (3 Suppl. 66), S7-14. van Vollenhoven RF, Geborek P, Forslind K et al. (2012) Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 379 (9827), 1712-20. Saag KG, Teng GG, Patkar NM et al. (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59, 762-84. Thompson AE, Rieder SW, Pope JE (2011) Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 63, 1479-85. Fautrel B, Constantin A, Morel J et al. (2006) Recommendations of the French Society for Rheumatology. TNFα antagonist therapy in rheumatoid arthritis. Joint Bone Spine 73, 433-41. Lichauco JJ, Tankeh-Torres SA, Navarra SV et al. (2006) Philippine guidelines on the screening for tuberculosis prior to the use of biologic agents. APLAR J Rheumatol 9, 184-92. da Mota LM, Cruz BA, Brenol CV et al. (2012) 2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis. Rev Bras Reumatol 52, 152-74. Deighton C, Hyrich K, Ding T et al. (2010) BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford) 49, 1197-9. Smolen JS, Schoels MM, Nishimoto N et al. (2013) Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 72, 482-92. Ǿstensen M, Andreoli L, Brucato A et al. (2014) State of the Art: reproduction and Pregnancy in Rheumatic Diseases. Autoimmun Rev 14, 376-86. van der Heijde D, Tanaka Y, Fleischmann R et al. (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65, 559-70. Rheumatoid Arthritis Study Group of the Portuguese Society of Rheumatology (2007) Portuguese guidelines for the use of biological agents in rheumatoid arthritis - December 2007 update. Acta Reumatol Port 32, 363-6. Caporali R, Caprioli M, Bobbio-Pallavicini F et al. (2008) DMARDS and infections in rheumatoid arthritis. Autoimmun Rev 8, 139-43. Ruyssen-Witrand A, Guernec G, Nigon D et al. (2014) Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes. Ann Rheum Dis 74, 1676-83. Katchamart W, Trudeau J, Phumethum V et al. (2009) Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 68, 1105-12. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365, 2205-19. Scott DL, Ibrahim F, Farewell V et al. (2015) Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ 350, h1046. Misra R, Sharma BL, Gupta R et al. (2008) Indian Rheumatology Association consensus statement on the management of adults with rheumatoid arthritis. Indian J Rheumatol 3 (Suppl. 3), 1-16. Kennedy T, McCabe C, Struthers G et al. (2005) BSR guidelines on standards of care for persons with rheumatoid arthritis. Rheumatology (Oxford) 44, 553-6. Kwong YL, Anderson BO, Advani R et al. (2009) Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10, 1093-101. Mok CC, Tam LS, Chan TH et al. (2011) Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol 30, 303-12. Sekiguchi N, Kameda H, Amano K et al. (2006) Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. Mod Rheumatol 16, 85-91. Fautrel B, Pham T, Mouterde G et al. (2007) Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 74, 627-37. Breedveld FC, Weisman MH, Kavanaugh AF et al. (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (1), 26-37. Turesson C, Jacobsson L, Bergström U (1999) Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 38, 668-74. Lipsky PE, van der Heijde DM, St Clair EW et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343, 1594-602. Moreland L (2005) Unmet needs in rheumatoid arthritis. Arthritis Res Ther 7 (Suppl. 3), S2-8. Bukhari M, Abernethy R, Deighton C et al. (2011) BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford) 50, 2311-3. Burmester GR, Blanco R, Charles-Schoeman C et al. (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381 (9865), 451-60. Koike R, Harigai M, Atsumi T et al. (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19, 351-7. Luqmani R, Hennell S, Estrach C et al. (2006) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford) 45, 1167-9. Kawai S, Takeuchi T, Yamamoto K et al. (2011) Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs-a multicenter, double-blind, parallel-group trial. Mod Rheumatol 21, 458-68. British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60, 800-5. van Vollenhoven RF, Fleischmann R, Cohen S et al. (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367, 508-19. Luqmani R, Hennell S, Estrach C et al. (2009) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford) 48, 436-9. Schoels M, Smolen JS (2012) Treating rheumatoid arthritis to target: evidence-based recommendations for enhanced disease management. Reumatol Clin 8 (1), 1-2. Dudler J, Finckh A, Kyburz D et al. (2010) Swiss consensus statement: recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis. Swiss Med Wkly 140, w13073. Filipovic I, Walker D, Forster F et al. (2011) Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 50, 1083-90. Miyasaka N, Takeuchi T, Eguchi K (2005) Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol 15, 4-8. Smolen JS, Keystone EC, Emery P et al. (2007) Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 66, 143-50. Bongartz T, Warren FC, Mines D et al. (2009) Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 68, 1177-83. Schieir O, Hazlewood G, Akhavan P et al. (2010) Time to ADAPTE: a novel methodology for the development of national clinical practice guidelines to expedite dissemination [abstract]. Ann Rheum Dis 69 (Suppl. 3), 652. Mouterde G, Dernis E, Ruyssen-Witrand A et al. (2010) Indications of glucocorticoids in early arthritis and rheumatoid arthritis: recommendations for clinical practice based on data from the literature and expert opinion. Joint Bone Spine 77, 597-603. Gorter SL, Bijlsma JW, Cutolo M et al. (2010) Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69, 1010-4. Albrecht K, Krüger K, Wollenhaupt J et al. (2014) German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Rheumatol Int 34 (1), 1-9. Emery P, Breedveld FC, Dougados M et al. (2002) Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 61, 290-7. Emery P, Reginster JY, Appelboom T et al. (2001) WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatolog 2006; 73 2013; 65 2013; 369 2006; 295 2014; 24 2008; 8 2010; 140 2008; 3 2005; 60 2010; 182 2007; 74 2012; 59 2012; 367 2007; 32 2001; 40 2001; 85 2009; 48 2012; 52 2003; 12 2004; 33 2009; 10 2010; 69 2007; 370 2006; 24 2011; 70 2002; 46 2013; 159 2013; 53 2011; 63 2003; 48 2014; 14 2011; 21 2005; 72 2007; 3 2009; 19 2012; 379 2007; 66 2011; 29 2011; 365 2012; 64 2010; 8 2007; 17 2010; 77 2009; 68 2010; 37 2010; 35 2009; 61 2006; 54 2006; 16 2006; 9 2009 2008; 58 2011; 30 2008; 59 2012; 39 2011; 36 2008; 123 2013; 381 2005; 44 2001; 323 2012; 30 2015; 350 2002; 69 2010; 49 2004; 50 2003; 107 2006; 45 2002; 61 1999; 38 2013; 72 2011; 50 2005; 7 2009; 7 2000; 343 2014; 74 2005; 15 2014; 73 2012; 7 2003; 62 2014; 34 2012; 8 e_1_2_14_73_1 e_1_2_14_96_1 Fonseca JE (e_1_2_14_39_1) 2011; 36 e_1_2_14_31_1 e_1_2_14_50_1 e_1_2_14_92_1 e_1_2_14_35_1 e_1_2_14_12_1 e_1_2_14_77_1 e_1_2_14_16_1 e_1_2_14_6_1 e_1_2_14_107_1 e_1_2_14_103_1 e_1_2_14_2_1 e_1_2_14_20_1 e_1_2_14_62_1 e_1_2_14_81_1 e_1_2_14_24_1 e_1_2_14_43_1 e_1_2_14_66_1 e_1_2_14_28_1 Fonseca JE (e_1_2_14_55_1) 2010; 35 e_1_2_14_89_1 e_1_2_14_47_1 Caporali R (e_1_2_14_37_1) 2011; 29 e_1_2_14_72_1 e_1_2_14_95_1 e_1_2_14_30_1 e_1_2_14_53_1 e_1_2_14_91_1 e_1_2_14_11_1 e_1_2_14_34_1 Favalli EG (e_1_2_14_38_1) 2011; 29 e_1_2_14_57_1 e_1_2_14_15_1 e_1_2_14_76_1 e_1_2_14_99_1 e_1_2_14_7_1 Rheumatoid Arthritis Study Group of the Portuguese Society of Rheumatology (e_1_2_14_54_1) 2007; 32 Blay P (e_1_2_14_85_1) 2012; 30 e_1_2_14_104_1 e_1_2_14_84_1 e_1_2_14_100_1 e_1_2_14_42_1 e_1_2_14_80_1 e_1_2_14_3_1 e_1_2_14_61_1 e_1_2_14_23_1 e_1_2_14_46_1 e_1_2_14_65_1 e_1_2_14_88_1 e_1_2_14_69_1 Cardiel MH (e_1_2_14_58_1) 2006; 45 Dudler J (e_1_2_14_41_1) 2010; 140 e_1_2_14_94_1 e_1_2_14_75_1 e_1_2_14_52_1 e_1_2_14_90_1 e_1_2_14_71_1 e_1_2_14_10_1 e_1_2_14_56_1 e_1_2_14_33_1 e_1_2_14_98_1 Nordgaard‐Lassen I (e_1_2_14_44_1) 2012; 59 e_1_2_14_79_1 Schieir O (e_1_2_14_14_1) 2010; 69 e_1_2_14_8_1 e_1_2_14_105_1 e_1_2_14_60_1 e_1_2_14_83_1 e_1_2_14_101_1 e_1_2_14_64_1 e_1_2_14_4_1 e_1_2_14_68_1 e_1_2_14_22_1 e_1_2_14_87_1 e_1_2_14_49_1 e_1_2_14_26_1 e_1_2_14_19_1 e_1_2_14_74_1 e_1_2_14_97_1 e_1_2_14_51_1 e_1_2_14_70_1 e_1_2_14_93_1 e_1_2_14_13_1 e_1_2_14_32_1 e_1_2_14_17_1 e_1_2_14_36_1 e_1_2_14_59_1 e_1_2_14_78_1 e_1_2_14_29_1 Valesini G (e_1_2_14_45_1) 2006; 24 e_1_2_14_5_1 e_1_2_14_9_1 e_1_2_14_106_1 e_1_2_14_102_1 e_1_2_14_86_1 e_1_2_14_63_1 Mota LM (e_1_2_14_27_1) 2013; 53 e_1_2_14_40_1 e_1_2_14_82_1 e_1_2_14_67_1 e_1_2_14_21_1 e_1_2_14_25_1 e_1_2_14_48_1 e_1_2_14_18_1 26644091 - Int J Rheum Dis. 2015 Nov;18(8):917 |
| References_xml | – reference: Westhovens R, Yocum D, Han J et al. (2006) The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54, 1075-86. – reference: Salaffi F, Carotti M, Gasparini S et al. (2009) The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 7, 25. – reference: Smolen JS, Keystone EC, Emery P et al. (2007) Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 66, 143-50. – reference: van Vollenhoven RF, Geborek P, Forslind K et al. (2012) Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 379 (9827), 1712-20. – reference: Fautrel B, Pham T, Mouterde G et al. (2007) Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 74, 627-37. – reference: Moreland LW, O'Dell JR, Paulus HE et al. (2012) A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 64, 2824-35. – reference: Kennedy T, McCabe C, Struthers G et al. (2005) BSR guidelines on standards of care for persons with rheumatoid arthritis. Rheumatology (Oxford) 44, 553-6. – reference: Mouterde G, Dernis E, Ruyssen-Witrand A et al. (2010) Indications of glucocorticoids in early arthritis and rheumatoid arthritis: recommendations for clinical practice based on data from the literature and expert opinion. Joint Bone Spine 77, 597-603. – reference: Koike R, Takeuchi T, Eguchi K et al. (2007) Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 17, 451-8. – reference: Harbour R, Miller J (2001) A new system for grading recommendations in evidence based guidelines. BMJ 323 (7308), 334-6. – reference: Breedveld FC, Weisman MH, Kavanaugh AF et al. (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (1), 26-37. – reference: Saag KG, Teng GG, Patkar NM et al. (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59, 762-84. – reference: Moulis G, Sommet A, Béné J et al. (2012) Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS ONE 7, e48991. – reference: Buch MH, Smolen JS, Betteridge N et al. (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70, 909-20. – reference: Lau CS, Feng PH (2007) Rheumatology without borders. Nat Clin Pract Rheumatol 3, 305. – reference: Le Blay P, Mouterde G, Barnetche T et al. (2012) Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. Clin Exp Rheumatol 30, 756-64. – reference: Brouwers MC, Kho ME, Browman GP et al. (2010) AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 182(18), E839-42. – reference: Mariette X, Salmon D (2003) French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 62, 791. – reference: Bongartz T, Warren FC, Mines D et al. (2009) Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 68, 1177-83. – reference: Favalli EG, Caporali R, Sinigaglia L et al. (2011) Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. Clin Exp Rheumatol 29 (3 Suppl. 66), S15-27. – reference: British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60, 800-5. – reference: Ǿstensen M, Andreoli L, Brucato A et al. (2014) State of the Art: reproduction and Pregnancy in Rheumatic Diseases. Autoimmun Rev 14, 376-86. – reference: Emery P, Breedveld FC, Dougados M et al. (2002) Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 61, 290-7. – reference: Hara M, Abe T, Sugawara S et al. (2007) Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol 17 (1), 1-9. – reference: Combe B, Landewe R, Lukas C et al. (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66 (1), 34-45. – reference: Gaujoux-Viala C, Smolen JS, Landewé R et al. (2010) Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69, 1004-9. – reference: Elkayam O, Caspi D, Reitblatt T et al. (2004) The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 33, 283-8. – reference: Bukhari M, Abernethy R, Deighton C et al. (2011) BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford) 50, 2311-3. – reference: Emery P, Reginster JY, Appelboom T et al. (2001) WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) 40, 699-702. – reference: Deighton C, Hyrich K, Ding T et al. (2010) BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford) 49, 1197-9. – reference: Gorter SL, Bijlsma JW, Cutolo M et al. (2010) Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69, 1010-4. – reference: Askling J, Fored CM, Brandt L et al. (2007) Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66, 1339-44. – reference: Verstappen SM, King Y, Watson KD et al. (2011) Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the BSR Biologics Register. Ann Rheum Dis 70, 823-6. – reference: Smolen JS, Schoels MM, Nishimoto N et al. (2013) Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 72, 482-92. – reference: Takeuchi T, Kawai S, Yamamoto K et al. (2014) Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. Mod Rheumatol 24 (1), 8-16. – reference: da Mota LM, Cruz BA, Brenol CV et al. (2013) Guidelines for the drug treatment of rheumatoid arthritis. Rev Bras Reumatol 53, 158-83. – reference: Knevel R, Schoels M, Huizinga TW et al. (2010) Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69, 987-94. – reference: Flavell KJ, Biddulph JP, Powell JE et al. (2001) South Asian ethnicity and material deprivation increase the risk of Epstein-Barr virus infection in childhood Hodgkin's disease. Br J Cancer 85, 350-6. – reference: Fleischmann R, Kremer J, Cush J et al. (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367, 495-507. – reference: Lichauco JJ, Tankeh-Torres SA, Navarra SV et al. (2006) Philippine guidelines on the screening for tuberculosis prior to the use of biologic agents. APLAR J Rheumatol 9, 184-92. – reference: Bongartz T, Sutton AJ, Sweeting MJ et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-85. – reference: Turesson C, Jacobsson L, Bergström U (1999) Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 38, 668-74. – reference: Bykerk VP, Akhavan P, Hazlewood GS et al. (2012) Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 39, 1559-82. – reference: Misra R, Sharma BL, Gupta R et al. (2008) Indian Rheumatology Association consensus statement on the management of adults with rheumatoid arthritis. Indian J Rheumatol 3 (Suppl. 3), 1-16. – reference: Smolen JS, Aletaha D, Koeller M et al. (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370 (9602), 1861-74. – reference: Bombardier C, Hazlewood GS, Akhavan P et al. (2012) Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol 39, 1583-602. – reference: Valesini G, Montecucco C, Cutolo M (2006) Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy. Clin Exp Rheumatol 24, 413-23. – reference: Keystone EC, Kavanaugh AF, Sharp JT et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50, 1400-11. – reference: Mok CC, Tam LS, Chan TH et al. (2011) Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol 30, 303-12. – reference: Weinblatt ME, Keystone EC, Furst DE et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (1), 35-45. – reference: Westlake SL, Colebatch AN, Baird J et al. (2011) Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 50, 518-31. – reference: Sekiguchi N, Kameda H, Amano K et al. (2006) Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. Mod Rheumatol 16, 85-91. – reference: Dudler J, Finckh A, Kyburz D et al. (2010) Swiss consensus statement: recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis. Swiss Med Wkly 140, w13073. – reference: Singh JA, Furst DE, Bharat A et al. (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64, 625-39. – reference: Chung ES, Packer M, Lo KH et al. (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133-40. – reference: Gettings L (2010) Psychological well-being in rheumatoid arthritis: a review of the literature. Musculoskeletal Care 8, 99-106. – reference: van Vollenhoven RF, Fleischmann R, Cohen S et al. (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367, 508-19. – reference: Smolen JS, Landewé R, Breedveld FC et al. (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73, 492-509. – reference: O'Dell JR, Mikuls TR, Taylor TH et al. (2013) Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 369, 307-18. – reference: AGREE Collaboration (2003) Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 12 (1), 18-23. – reference: Fautrel B, Constantin A, Morel J et al. (2006) Recommendations of the French Society for Rheumatology. TNFα antagonist therapy in rheumatoid arthritis. Joint Bone Spine 73, 433-41. – reference: Miyasaka N, Takeuchi T, Eguchi K (2005) Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol 15, 4-8. – reference: Smolen JS, Aletaha D, Bijlsma JW et al. (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69, 631-7. – reference: Caporali R, Conti F, Alivernini S et al. (2011) Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol 29 (3 Suppl. 66), S7-14. – reference: Scott DL, Ibrahim F, Farewell V et al. (2015) Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ 350, h1046. – reference: Lipsky PE, van der Heijde DM, St Clair EW et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343, 1594-602. – reference: Kwong YL, Anderson BO, Advani R et al. (2009) Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10, 1093-101. – reference: Thompson AE, Rieder SW, Pope JE (2011) Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 63, 1479-85. – reference: Gossec L, Fautrel B, Pham T et al. (2005) Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 72, 229-34. – reference: Visser K, Katchamart W, Loza E et al. (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68, 1086-93. – reference: Moreland L (2005) Unmet needs in rheumatoid arthritis. Arthritis Res Ther 7 (Suppl. 3), S2-8. – reference: Schoels M, Smolen JS (2012) Treating rheumatoid arthritis to target: evidence-based recommendations for enhanced disease management. Reumatol Clin 8 (1), 1-2. – reference: van der Heijde D, Tanaka Y, Fleischmann R et al. (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65, 559-70. – reference: Smolen JS, Landewé R, Breedveld FC et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69, 964-75. – reference: Luqmani R, Hennell S, Estrach C et al. (2009) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford) 48, 436-9. – reference: Schieir O, Hazlewood G, Akhavan P et al. (2010) Time to ADAPTE: a novel methodology for the development of national clinical practice guidelines to expedite dissemination [abstract]. Ann Rheum Dis 69 (Suppl. 3), 652. – reference: Burmester GR, Blanco R, Charles-Schoeman C et al. (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381 (9865), 451-60. – reference: Koike R, Harigai M, Atsumi T et al. (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19, 351-7. – reference: Caporali R, Caprioli M, Bobbio-Pallavicini F et al. (2008) DMARDS and infections in rheumatoid arthritis. Autoimmun Rev 8, 139-43. – reference: Glaser SL, Gulley ML, Clarke CA et al. (2008) Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations. Int J Cancer 123, 1499-507. – reference: Cardiel MH, PANLAR group, GLADAR group (2006) First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. Rheumatology (Oxford) 45(Suppl.2), ii7-22. – reference: Lu LJ, Bao CD, Dai M et al. (2009) Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum 61, 979-87. – reference: Fonseca JE, Bernardes M, Canhão H et al. (2011) Portuguese guidelines for the use of biological agents in rheumatoid arthritis - October 2011 update. Acta Reumatol Port 36, 385-8. – reference: Ledingham J, Deighton CBritish Society for Rheumatology Standards, Guidelines and Audit Working Group (2005) Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 44, 157-63. – reference: Filipovic I, Walker D, Forster F et al. (2011) Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 50, 1083-90. – reference: Katchamart W, Trudeau J, Phumethum V et al. (2009) Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 68, 1105-12. – reference: Kremer J, Li ZG, Hall S et al. (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159, 253-61. – reference: Doran MF, Crowson CS, Pond GR et al. (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46, 2287-93. – reference: Listing J, Strangfeld A, Kekow J et al. (2008) Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 58, 667-77. – reference: Rheumatoid Arthritis Study Group of the Portuguese Society of Rheumatology (2007) Portuguese guidelines for the use of biological agents in rheumatoid arthritis - December 2007 update. Acta Reumatol Port 32, 363-6. – reference: Albrecht K, Krüger K, Wollenhaupt J et al. (2014) German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Rheumatol Int 34 (1), 1-9. – reference: Fonseca JE, Canhão H, Reis M et al. (2010) Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 update. Acta Reumatol Port 35 (1), 95-8. – reference: Ruyssen-Witrand A, Guernec G, Nigon D et al. (2014) Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes. Ann Rheum Dis 74, 1676-83. – reference: da Mota LM, Cruz BA, Brenol CV et al. (2012) 2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis. Rev Bras Reumatol 52, 152-74. – reference: Nordgaard-Lassen I, Dahlerup JF, Belard E et al. (2012) Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J 59 (7), C4480. – reference: Salmon D, GTI group, AFSSAPS group (2002) Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine 69, 170-2. – reference: Kawai S, Takeuchi T, Yamamoto K et al. (2011) Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs-a multicenter, double-blind, parallel-group trial. Mod Rheumatol 21, 458-68. – reference: McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365, 2205-19. – reference: Luqmani R, Hennell S, Estrach C et al. (2006) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford) 45, 1167-9. – reference: Miyasaka N, Takeuchi T, Eguchi K (2006) Guidelines for the proper use of etanercept in Japan. Mod Rheumatol 16, 63-7. – reference: Pham T, Gossec L, Fautrel B et al. (2005) Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 72, 222-8. – reference: Katchamart W, Bourré-Tessier J, Donka T et al. (2010) Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. J Rheumatol 37, 1422-30. – volume: 72 start-page: 222 year: 2005 end-page: 8 article-title: Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion publication-title: Joint Bone Spine – volume: 367 start-page: 508 year: 2012 end-page: 19 article-title: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis publication-title: N Engl J Med – volume: 64 start-page: 2824 year: 2012 end-page: 35 article-title: A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial publication-title: Arthritis Rheum – volume: 21 start-page: 458 year: 2011 end-page: 68 article-title: Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs–a multicenter, double‐blind, parallel‐group trial publication-title: Mod Rheumatol – volume: 17 start-page: 1 issue: 1 year: 2007 end-page: 9 article-title: Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double‐blind, parallel‐group study publication-title: Mod Rheumatol – volume: 70 start-page: 909 year: 2011 end-page: 20 article-title: Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis publication-title: Ann Rheum Dis – volume: 8 start-page: 99 year: 2010 end-page: 106 article-title: Psychological well‐being in rheumatoid arthritis: a review of the literature publication-title: Musculoskeletal Care – volume: 53 start-page: 158 year: 2013 end-page: 83 article-title: Guidelines for the drug treatment of rheumatoid arthritis publication-title: Rev Bras Reumatol – volume: 3 start-page: 305 year: 2007 article-title: Rheumatology without borders publication-title: Nat Clin Pract Rheumatol – volume: 66 start-page: 34 issue: 1 year: 2007 end-page: 45 article-title: EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) publication-title: Ann Rheum Dis – volume: 49 start-page: 1197 year: 2010 end-page: 9 article-title: BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy publication-title: Rheumatology (Oxford) – volume: 65 start-page: 559 year: 2013 end-page: 70 article-title: Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve‐month data from a twenty‐four‐month phase III randomized radiographic study publication-title: Arthritis Rheum – volume: 30 start-page: 756 year: 2012 end-page: 64 article-title: Risk of malignancy including non‐melanoma skin cancers with anti‐tumor necrosis factor therapy in patients with rheumatoid arthritis: meta‐analysis of registries and systematic review of long‐term extension studies publication-title: Clin Exp Rheumatol – volume: 69 start-page: 987 year: 2010 end-page: 94 article-title: Current evidence for a strategic approach to the management of rheumatoid arthritis with disease‐modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis publication-title: Ann Rheum Dis – volume: 44 start-page: 157 year: 2005 end-page: 63 article-title: Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001) publication-title: Rheumatology (Oxford) – volume: 69 start-page: 964 year: 2010 end-page: 75 article-title: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs publication-title: Ann Rheum Dis – volume: 68 start-page: 1105 year: 2009 end-page: 12 article-title: Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non‐biological disease‐modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta‐analysis publication-title: Ann Rheum Dis – volume: 159 start-page: 253 year: 2013 end-page: 61 article-title: Tofacitinib in combination with nonbiologic disease‐modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial publication-title: Ann Intern Med – volume: 50 start-page: 1400 year: 2004 end-page: 11 article-title: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti‐tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo‐controlled, 52‐week trial publication-title: Arthritis Rheum – volume: 68 start-page: 1086 year: 2009 end-page: 93 article-title: Multinational evidence‐based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative publication-title: Ann Rheum Dis – volume: 69 start-page: 631 year: 2010 end-page: 7 article-title: Treating rheumatoid arthritis to target: recommendations of an international task force publication-title: Ann Rheum Dis – volume: 140 start-page: w13073 year: 2010 article-title: Swiss consensus statement: recommendations for optimising re‐treatment with MabThera (rituximab) in rheumatoid arthritis publication-title: Swiss Med Wkly – volume: 66 start-page: 143 year: 2007 end-page: 50 article-title: Consensus statement on the use of rituximab in patients with rheumatoid arthritis publication-title: Ann Rheum Dis – volume: 85 start-page: 350 year: 2001 end-page: 6 article-title: South Asian ethnicity and material deprivation increase the risk of Epstein‐Barr virus infection in childhood Hodgkin's disease publication-title: Br J Cancer – volume: 24 start-page: 413 year: 2006 end-page: 23 article-title: Recommendations for the use of biologic (TNF‐alpha blocking) agents in the treatment of rheumatoid arthritis in Italy publication-title: Clin Exp Rheumatol – volume: 32 start-page: 363 year: 2007 end-page: 6 article-title: Portuguese guidelines for the use of biological agents in rheumatoid arthritis – December 2007 update publication-title: Acta Reumatol Port – volume: 33 start-page: 283 year: 2004 end-page: 8 article-title: The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis publication-title: Semin Arthritis Rheum – volume: 16 start-page: 85 year: 2006 end-page: 91 article-title: Efficacy and safety of bucillamine, a D‐penicillamine analogue, in patients with active rheumatoid arthritis publication-title: Mod Rheumatol – volume: 50 start-page: 1083 year: 2011 end-page: 90 article-title: Quantifying the economic burden of productivity loss in rheumatoid arthritis publication-title: Rheumatology (Oxford) – volume: 59 start-page: C4480 issue: 7 year: 2012 article-title: Guidelines for screening, prophylaxis and critical information prior to initiating anti‐TNF‐alpha treatment publication-title: Dan Med J – volume: 370 start-page: 1861 issue: 9602 year: 2007 end-page: 74 article-title: New therapies for treatment of rheumatoid arthritis publication-title: Lancet – volume: 17 start-page: 451 year: 2007 end-page: 8 article-title: Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis publication-title: Mod Rheumatol – volume: 12 start-page: 18 issue: 1 year: 2003 end-page: 23 article-title: Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project publication-title: Qual Saf Health Care – volume: 350 start-page: h1046 year: 2015 article-title: Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti‐rheumatic drugs in established rheumatoid arthritis: TACIT non‐inferiority randomised controlled trial publication-title: BMJ – volume: 182 start-page: E839 issue: 18 year: 2010 end-page: 42 article-title: AGREE II: advancing guideline development, reporting and evaluation in health care publication-title: CMAJ – volume: 10 start-page: 1093 year: 2009 end-page: 101 article-title: Management of T‐cell and natural‐killer‐cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009 publication-title: Lancet Oncol – volume: 35 start-page: 95 issue: 1 year: 2010 end-page: 8 article-title: Portuguese guidelines for the use of biological agents in rheumatoid arthritis – March 2010 update publication-title: Acta Reumatol Port – volume: 7 start-page: S2 issue: Suppl. 3 year: 2005 end-page: 8 article-title: Unmet needs in rheumatoid arthritis publication-title: Arthritis Res Ther – volume: 15 start-page: 4 year: 2005 end-page: 8 article-title: Official Japanese guidelines for the use of infliximab for rheumatoid arthritis publication-title: Mod Rheumatol – volume: 58 start-page: 667 year: 2008 end-page: 77 article-title: Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? publication-title: Arthritis Rheum – volume: 29 start-page: S15 issue: 3 Suppl. 66 year: 2011 end-page: 27 article-title: Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety publication-title: Clin Exp Rheumatol – volume: 73 start-page: 492 year: 2014 end-page: 509 article-title: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs: 2013 update publication-title: Ann Rheum Dis – volume: 54 start-page: 1075 year: 2006 end-page: 86 article-title: The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo‐controlled trial publication-title: Arthritis Rheum – volume: 77 start-page: 597 year: 2010 end-page: 603 article-title: Indications of glucocorticoids in early arthritis and rheumatoid arthritis: recommendations for clinical practice based on data from the literature and expert opinion publication-title: Joint Bone Spine – volume: 3 start-page: 1 issue: Suppl. 3 year: 2008 end-page: 16 article-title: Indian Rheumatology Association consensus statement on the management of adults with rheumatoid arthritis publication-title: Indian J Rheumatol – volume: 48 start-page: 35 issue: 1 year: 2003 end-page: 45 article-title: Adalimumab, a fully human anti‐tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial publication-title: Arthritis Rheum – year: 2009 – volume: 61 start-page: 979 year: 2009 end-page: 87 article-title: Multicenter, randomized, double‐blind, controlled trial of treatment of active rheumatoid arthritis with T‐614 compared with methotrexate publication-title: Arthritis Rheum – volume: 379 start-page: 1712 issue: 9827 year: 2012 end-page: 20 article-title: Conventional combination treatment versus biological treatment in methotrexate‐refractory early rheumatoid arthritis: 2 year follow‐up of the randomised, non‐blinded, parallel‐group Swefot trial publication-title: Lancet – volume: 323 start-page: 334 issue: 7308 year: 2001 end-page: 6 article-title: A new system for grading recommendations in evidence based guidelines publication-title: BMJ – volume: 39 start-page: 1559 year: 2012 end-page: 82 article-title: Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease‐modifying antirheumatic drugs publication-title: J Rheumatol – volume: 30 start-page: 303 year: 2011 end-page: 12 article-title: Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology publication-title: Clin Rheumatol – volume: 61 start-page: 290 year: 2002 end-page: 7 article-title: Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide publication-title: Ann Rheum Dis – volume: 38 start-page: 668 year: 1999 end-page: 74 article-title: Extra‐articular rheumatoid arthritis: prevalence and mortality publication-title: Rheumatology (Oxford) – volume: 9 start-page: 184 year: 2006 end-page: 92 article-title: Philippine guidelines on the screening for tuberculosis prior to the use of biologic agents publication-title: APLAR J Rheumatol – volume: 73 start-page: 433 year: 2006 end-page: 41 article-title: Recommendations of the French Society for Rheumatology. TNFα antagonist therapy in rheumatoid arthritis publication-title: Joint Bone Spine – volume: 50 start-page: 2311 year: 2011 end-page: 3 article-title: BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis publication-title: Rheumatology (Oxford) – volume: 381 start-page: 451 issue: 9865 year: 2013 end-page: 60 article-title: Tofacitinib (CP‐690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial publication-title: Lancet – volume: 8 start-page: 139 year: 2008 end-page: 43 article-title: DMARDS and infections in rheumatoid arthritis publication-title: Autoimmun Rev – volume: 123 start-page: 1499 year: 2008 end-page: 507 article-title: Racial/ethnic variation in EBV‐positive classical Hodgkin lymphoma in California populations publication-title: Int J Cancer – volume: 74 start-page: 627 year: 2007 end-page: 37 article-title: Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with rheumatoid arthritis publication-title: Joint Bone Spine – volume: 69 start-page: 1004 year: 2010 end-page: 9 article-title: Current evidence for the management of rheumatoid arthritis with synthetic disease‐modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis publication-title: Ann Rheum Dis – volume: 39 start-page: 1583 year: 2012 end-page: 602 article-title: Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease‐modifying antirheumatic drugs: part II safety publication-title: J Rheumatol – volume: 8 start-page: 1 issue: 1 year: 2012 end-page: 2 article-title: Treating rheumatoid arthritis to target: evidence‐based recommendations for enhanced disease management publication-title: Reumatol Clin – volume: 46 start-page: 2287 year: 2002 end-page: 93 article-title: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population‐based study publication-title: Arthritis Rheum – volume: 59 start-page: 762 year: 2008 end-page: 84 article-title: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis publication-title: Arthritis Rheum – volume: 62 start-page: 791 year: 2003 article-title: French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers publication-title: Ann Rheum Dis – volume: 37 start-page: 1422 year: 2010 end-page: 30 article-title: Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis publication-title: J Rheumatol – volume: 70 start-page: 823 year: 2011 end-page: 6 article-title: Anti‐TNF therapies and pregnancy: outcome of 130 pregnancies in the BSR Biologics Register publication-title: Ann Rheum Dis – volume: 72 start-page: 482 year: 2013 end-page: 92 article-title: Consensus statement on blocking the effects of interleukin‐6 and in particular by interleukin‐6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions publication-title: Ann Rheum Dis – volume: 40 start-page: 699 year: 2001 end-page: 702 article-title: WHO Collaborating Centre consensus meeting on anti‐cytokine therapy in rheumatoid arthritis publication-title: Rheumatology (Oxford) – volume: 34 start-page: 1 issue: 1 year: 2014 end-page: 9 article-title: German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease‐modifying antirheumatic drugs publication-title: Rheumatol Int – volume: 365 start-page: 2205 year: 2011 end-page: 19 article-title: The pathogenesis of rheumatoid arthritis publication-title: N Engl J Med – volume: 52 start-page: 152 year: 2012 end-page: 74 article-title: 2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis publication-title: Rev Bras Reumatol – volume: 69 start-page: 652 issue: Suppl. 3 year: 2010 article-title: Time to ADAPTE: a novel methodology for the development of national clinical practice guidelines to expedite dissemination [abstract] publication-title: Ann Rheum Dis – volume: 74 start-page: 1676 year: 2014 end-page: 83 article-title: Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3‐year structural outcomes publication-title: Ann Rheum Dis – volume: 343 start-page: 1594 year: 2000 end-page: 602 article-title: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti‐Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group publication-title: N Engl J Med – volume: 7 start-page: e48991 year: 2012 article-title: Cancer risk of anti‐TNF‐α at recommended doses in adult rheumatoid arthritis: a meta‐analysis with intention to treat and per protocol analyses publication-title: PLoS ONE – volume: 68 start-page: 1177 year: 2009 end-page: 83 article-title: Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta‐analysis of randomised controlled trials publication-title: Ann Rheum Dis – volume: 63 start-page: 1479 year: 2011 end-page: 85 article-title: Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta‐analysis of randomized controlled trials publication-title: Arthritis Rheum – volume: 69 start-page: 170 year: 2002 end-page: 2 article-title: Recommendations about the prevention and management of tuberculosis in patients taking infliximab publication-title: Joint Bone Spine – volume: 50 start-page: 518 year: 2011 end-page: 31 article-title: Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review publication-title: Rheumatology – volume: 7 start-page: 25 year: 2009 article-title: The health‐related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people publication-title: Health Qual Life Outcomes – volume: 66 start-page: 1339 year: 2007 end-page: 44 article-title: Time‐dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists publication-title: Ann Rheum Dis – volume: 24 start-page: 8 issue: 1 year: 2014 end-page: 16 article-title: Post‐marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis publication-title: Mod Rheumatol – volume: 107 start-page: 3133 year: 2003 end-page: 40 article-title: Randomized, double‐blind, placebo‐controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor, in patients with moderate‐to‐severe heart failure: results of the anti‐TNF Therapy Against Congestive Heart Failure (ATTACH) trial publication-title: Circulation – volume: 45 start-page: ii7 issue: Suppl.2 year: 2006 end-page: 22 article-title: First Latin American position paper on the pharmacological treatment of rheumatoid arthritis publication-title: Rheumatology (Oxford) – volume: 44 start-page: 553 year: 2005 end-page: 6 article-title: BSR guidelines on standards of care for persons with rheumatoid arthritis publication-title: Rheumatology (Oxford) – volume: 36 start-page: 385 year: 2011 end-page: 8 article-title: Portuguese guidelines for the use of biological agents in rheumatoid arthritis – October 2011 update publication-title: Acta Reumatol Port – volume: 369 start-page: 307 year: 2013 end-page: 18 article-title: Therapies for active rheumatoid arthritis after methotrexate failure publication-title: N Engl J Med – volume: 16 start-page: 63 year: 2006 end-page: 7 article-title: Guidelines for the proper use of etanercept in Japan publication-title: Mod Rheumatol – volume: 48 start-page: 436 year: 2009 end-page: 9 article-title: British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years) publication-title: Rheumatology (Oxford) – volume: 60 start-page: 800 year: 2005 end-page: 5 article-title: BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti‐TNF‐alpha treatment publication-title: Thorax – volume: 367 start-page: 495 year: 2012 end-page: 507 article-title: Placebo‐controlled trial of tofacitinib monotherapy in rheumatoid arthritis publication-title: N Engl J Med – volume: 14 start-page: 376 year: 2014 end-page: 86 article-title: State of the Art: reproduction and Pregnancy in Rheumatic Diseases publication-title: Autoimmun Rev – volume: 45 start-page: 1167 year: 2006 end-page: 9 article-title: British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years) publication-title: Rheumatology (Oxford) – volume: 64 start-page: 625 year: 2012 end-page: 39 article-title: 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis publication-title: Arthritis Care Res (Hoboken) – volume: 295 start-page: 2275 year: 2006 end-page: 85 article-title: Anti‐TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta‐analysis of rare harmful effects in randomized controlled trials publication-title: JAMA – volume: 19 start-page: 351 year: 2009 end-page: 7 article-title: Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti‐interleukin‐6 receptor monoclonal antibody, in rheumatoid arthritis publication-title: Mod Rheumatol – volume: 54 start-page: 26 issue: 1 year: 2006 end-page: 37 article-title: The PREMIER study: a multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment publication-title: Arthritis Rheum – volume: 29 start-page: S7 issue: 3 Suppl. 66 year: 2011 end-page: 14 article-title: Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy publication-title: Clin Exp Rheumatol – volume: 72 start-page: 229 year: 2005 end-page: 34 article-title: Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion publication-title: Joint Bone Spine – volume: 69 start-page: 1010 year: 2010 end-page: 4 article-title: Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis publication-title: Ann Rheum Dis – ident: e_1_2_14_51_1 doi: 10.3109/s10165-004-0357-7 – ident: e_1_2_14_72_1 doi: 10.1136/ard.2009.127225 – ident: e_1_2_14_96_1 doi: 10.1002/art.21519 – ident: e_1_2_14_69_1 doi: 10.3109/14397595.2013.854074 – volume: 36 start-page: 385 year: 2011 ident: e_1_2_14_39_1 article-title: Portuguese guidelines for the use of biological agents in rheumatoid arthritis – October 2011 update publication-title: Acta Reumatol Port – ident: e_1_2_14_43_1 doi: 10.1016/j.jbspin.2004.10.011 – ident: e_1_2_14_97_1 doi: 10.1002/art.20217 – ident: e_1_2_14_29_1 doi: 10.3899/jrheum.110207 – ident: e_1_2_14_12_1 – ident: e_1_2_14_66_1 doi: 10.1002/art.24643 – ident: e_1_2_14_78_1 doi: 10.1136/bmj.h1046 – ident: e_1_2_14_90_1 doi: 10.1093/rheumatology/keq316 – ident: e_1_2_14_15_1 doi: 10.1136/qhc.12.1.18 – ident: e_1_2_14_73_1 doi: 10.1136/ard.2009.126532 – ident: e_1_2_14_2_1 doi: 10.1056/NEJMra1004965 – volume: 32 start-page: 363 year: 2007 ident: e_1_2_14_54_1 article-title: Portuguese guidelines for the use of biological agents in rheumatoid arthritis – December 2007 update publication-title: Acta Reumatol Port – ident: e_1_2_14_47_1 doi: 10.3899/jrheum.120165 – ident: e_1_2_14_53_1 doi: 10.1093/rheumatology/keh464 – ident: e_1_2_14_60_1 doi: 10.1016/S1297-319X(02)00387-1 – ident: e_1_2_14_101_1 doi: 10.1056/NEJMoa1109071 – ident: e_1_2_14_8_1 doi: 10.1016/S0140-6736(07)60784-3 – ident: e_1_2_14_13_1 – ident: e_1_2_14_95_1 doi: 10.1056/NEJM200011303432202 – ident: e_1_2_14_19_1 doi: 10.1002/acr.21641 – ident: e_1_2_14_24_1 doi: 10.1007/s10067-010-1596-y – ident: e_1_2_14_40_1 doi: 10.1093/rheumatology/keq006a – ident: e_1_2_14_46_1 doi: 10.1136/ard.62.8.791 – ident: e_1_2_14_75_1 doi: 10.1016/S0140-6736(12)60027-0 – ident: e_1_2_14_86_1 doi: 10.1371/journal.pone.0048991 – ident: e_1_2_14_71_1 doi: 10.1136/ard.2008.094474 – ident: e_1_2_14_4_1 doi: 10.1186/ar1736 – ident: e_1_2_14_83_1 doi: 10.1002/art.30310 – ident: e_1_2_14_63_1 doi: 10.1016/j.jbspin.2009.12.011 – ident: e_1_2_14_98_1 doi: 10.1002/art.21734 – ident: e_1_2_14_34_1 doi: 10.1136/annrheumdis-2012-202469 – ident: e_1_2_14_87_1 doi: 10.1136/ard.2010.140822 – volume: 30 start-page: 756 year: 2012 ident: e_1_2_14_85_1 article-title: Risk of malignancy including non‐melanoma skin cancers with anti‐tumor necrosis factor therapy in patients with rheumatoid arthritis: meta‐analysis of registries and systematic review of long‐term extension studies publication-title: Clin Exp Rheumatol – ident: e_1_2_14_31_1 doi: 10.1136/annrheumdis-2013-204906 – ident: e_1_2_14_106_1 – volume: 35 start-page: 95 issue: 1 year: 2010 ident: e_1_2_14_55_1 article-title: Portuguese guidelines for the use of biological agents in rheumatoid arthritis – March 2010 update publication-title: Acta Reumatol Port – ident: e_1_2_14_11_1 doi: 10.1016/S1470-2045(09)70265-7 – ident: e_1_2_14_70_1 doi: 10.1002/art.23721 – ident: e_1_2_14_65_1 doi: 10.3109/s10165-005-0466-y – ident: e_1_2_14_99_1 doi: 10.1016/j.autrev.2014.12.011 – ident: e_1_2_14_17_1 doi: 10.1136/bmj.323.7308.334 – ident: e_1_2_14_81_1 doi: 10.1001/jama.295.19.2275 – ident: e_1_2_14_33_1 – ident: e_1_2_14_9_1 doi: 10.1054/bjoc.2001.1872 – ident: e_1_2_14_68_1 doi: 10.3109/s10165-011-0425-8 – ident: e_1_2_14_21_1 doi: 10.1016/j.reuma.2011.07.002 – ident: e_1_2_14_20_1 doi: 10.1136/ard.2009.123919 – ident: e_1_2_14_74_1 doi: 10.1136/ard.2008.099861 – ident: e_1_2_14_104_1 doi: 10.1056/NEJMoa1112072 – ident: e_1_2_14_6_1 doi: 10.1093/rheumatology/keq399 – ident: e_1_2_14_23_1 doi: 10.1016/S0973-3698(10)60373-1 – ident: e_1_2_14_5_1 doi: 10.1186/1477-7525-7-25 – ident: e_1_2_14_35_1 doi: 10.1016/j.jbspin.2006.04.001 – ident: e_1_2_14_94_1 doi: 10.1002/art.10697 – ident: e_1_2_14_18_1 doi: 10.1136/annrheumdis-2013-204573 – ident: e_1_2_14_36_1 doi: 10.1016/j.jbspin.2007.10.001 – ident: e_1_2_14_3_1 doi: 10.1093/rheumatology/38.7.668 – ident: e_1_2_14_49_1 doi: 10.3109/s10165-009-0197-6 – ident: e_1_2_14_56_1 doi: 10.1093/rheumatology/ken450a – ident: e_1_2_14_105_1 doi: 10.1016/S0140-6736(12)61424-X – volume: 69 start-page: 652 issue: 3 year: 2010 ident: e_1_2_14_14_1 article-title: Time to ADAPTE: a novel methodology for the development of national clinical practice guidelines to expedite dissemination [abstract] publication-title: Ann Rheum Dis – ident: e_1_2_14_52_1 doi: 10.3109/s10165-007-0626-3 – ident: e_1_2_14_61_1 doi: 10.1093/rheumatology/keh554 – ident: e_1_2_14_92_1 doi: 10.1016/j.autrev.2008.05.001 – volume: 29 start-page: S15 issue: 3 year: 2011 ident: e_1_2_14_38_1 article-title: Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety publication-title: Clin Exp Rheumatol – ident: e_1_2_14_77_1 doi: 10.1056/NEJMoa1303006 – ident: e_1_2_14_107_1 doi: 10.1038/ncprheum0509 – volume: 53 start-page: 158 year: 2013 ident: e_1_2_14_27_1 article-title: Guidelines for the drug treatment of rheumatoid arthritis publication-title: Rev Bras Reumatol – ident: e_1_2_14_50_1 doi: 10.3109/s10165-006-0457-7 – ident: e_1_2_14_89_1 doi: 10.1002/art.23281 – volume: 140 start-page: w13073 year: 2010 ident: e_1_2_14_41_1 article-title: Swiss consensus statement: recommendations for optimising re‐treatment with MabThera (rituximab) in rheumatoid arthritis publication-title: Swiss Med Wkly – ident: e_1_2_14_91_1 doi: 10.1136/thx.2005.046797 – ident: e_1_2_14_76_1 doi: 10.1002/art.34498 – ident: e_1_2_14_64_1 doi: 10.1136/ard.2009.127332 – volume: 59 start-page: C4480 issue: 7 year: 2012 ident: e_1_2_14_44_1 article-title: Guidelines for screening, prophylaxis and critical information prior to initiating anti‐TNF‐alpha treatment publication-title: Dan Med J – ident: e_1_2_14_103_1 doi: 10.1002/art.37816 – ident: e_1_2_14_7_1 doi: 10.1002/msc.171 – ident: e_1_2_14_80_1 doi: 10.1093/rheumatology/40.6.699 – ident: e_1_2_14_42_1 doi: 10.1016/j.jbspin.2004.10.010 – ident: e_1_2_14_67_1 doi: 10.3109/s10165-006-0542-y – ident: e_1_2_14_10_1 doi: 10.1002/ijc.23741 – ident: e_1_2_14_25_1 doi: 10.1590/S0482-50042012000200002 – ident: e_1_2_14_82_1 doi: 10.1136/ard.2006.062760 – ident: e_1_2_14_32_1 doi: 10.1136/ard.2010.144998 – ident: e_1_2_14_100_1 doi: 10.1053/j.semarthrit.2003.10.003 – ident: e_1_2_14_79_1 doi: 10.1136/ard.2009.126748 – ident: e_1_2_14_93_1 doi: 10.1002/art.10524 – volume: 45 start-page: ii7 issue: 2 year: 2006 ident: e_1_2_14_58_1 article-title: First Latin American position paper on the pharmacological treatment of rheumatoid arthritis publication-title: Rheumatology (Oxford) – ident: e_1_2_14_88_1 doi: 10.1161/01.CIR.0000077913.60364.D2 – ident: e_1_2_14_59_1 doi: 10.1136/ard.2006.061002 – ident: e_1_2_14_48_1 doi: 10.1111/j.1479-8077.2006.00182.x – ident: e_1_2_14_102_1 doi: 10.7326/0003-4819-159-4-201308200-00006 – ident: e_1_2_14_57_1 doi: 10.1093/rheumatology/ker106a – ident: e_1_2_14_22_1 doi: 10.1136/ard.2005.044354 – volume: 24 start-page: 413 year: 2006 ident: e_1_2_14_45_1 article-title: Recommendations for the use of biologic (TNF‐alpha blocking) agents in the treatment of rheumatoid arthritis in Italy publication-title: Clin Exp Rheumatol – ident: e_1_2_14_62_1 doi: 10.1136/ard.61.4.290 – volume: 29 start-page: S7 issue: 3 year: 2011 ident: e_1_2_14_37_1 article-title: Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy publication-title: Clin Exp Rheumatol – ident: e_1_2_14_30_1 doi: 10.1093/rheumatology/kel215a – ident: e_1_2_14_16_1 doi: 10.1503/cmaj.090449 – ident: e_1_2_14_84_1 doi: 10.1136/ard.2008.094904 – ident: e_1_2_14_28_1 doi: 10.3899/jrheum.090978 – ident: e_1_2_14_26_1 doi: 10.1007/s00296-013-2848-3 – reference: 26644091 - Int J Rheum Dis. 2015 Nov;18(8):917 |
| SSID | ssj0061367 |
| Score | 2.3777506 |
| SecondaryResourceType | review_article |
| Snippet | Aims
Rheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines... Rheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines and... Aims Rheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines... AIMSRheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines and... |
| SourceID | proquest pubmed crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 685 |
| SubjectTerms | Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - therapy Consensus drug treatment Evidence-Based Medicine - standards Humans Rheumatism Rheumatoid arthritis Rheumatology Rheumatology - standards |
| Title | APLAR rheumatoid arthritis treatment recommendations |
| URI | https://api.istex.fr/ark:/67375/WNG-90SX3LC2-H/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2F1756-185X.12754 https://www.ncbi.nlm.nih.gov/pubmed/26334449 https://www.proquest.com/docview/1709465961 https://www.proquest.com/docview/1709706544 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3rSxwxEA9FofjF2tbH-ShbEPHLHrubx14-Hof2KCpiFe9bSHYnKOpduQdI__rOZB-oKEX6LWEnu8k8kpnN5BfG9nXqpUtcHssyh1i4JI-tAx9by7lFrQYIsIunZ2p4JX6OZJNNSGdhKnyI9ocbWUaYr8nArZs9MXJc91SMq82oSxjlhAhKGVvkFl20AFKKAMnCkchAK9Ia3IdyeV60f7YuLROLH19zOp_7sGEROv7EXNP9KvfkrruYu27x5wWy43-Nb42t1i5q1K906jP7AOMv7ONpvQn_lYn--Un_IprewALd3cltGaH63QRwpKjNW48o0n7AUnVn02ydXR0fXQ6GcX35QlxIDKFinqUevMfwK0msQKclLwvkZokVrrQVVvgst15AAToHAYl3trAy96pIS52VfIMtjSdj2GKRl9rppOSpBBA4g_R6NuUlVjJfqCyBDus2rDdFjUxOF2TcmyZCIV4Y4oUJvOiww7bB7wqU423SgyDLls5O7yiXLZfm-uyH0cmvET8ZZGbYYbuNsE1txjN8GUa_SmqVdtj39jEaIO2q2DFMFhUN7RUL_NZmpSTtxzLFuRBC4wiDqP_VW4MCDIXt9zbYYSvoyskq-22XLc2nC9hDd2nuvgWL-Asm_ga5 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dT9swED8NkGAvYxuwdTCWSQjxkiqJP4IfKz5WtrZCfIi-WY5zFhNbO5VWmvbX7-ykEaAhhPZmK2c7PvvsO_v8O4AdlTpRJEUeizLHmBdJHpsCXWwMY4ZmNWKAXewPZPeSfx2K4Z23MBU-RHPg5iUjrNdewP2B9B0pp41PxrTdDNsepJwvwJKP6-2jGByeNRBS0kOShUeRgZinNbyP9-Z5UMG9nWnJM_n3v9TO-1ps2IaOV8HOO1B5n9y0Z9Oibf88wHb8vx6-hle1lhp1qmn1Bl7g6C0s9-t7-DXgndNe5yyaXOOMNN7x9zKiGXgd8JGixnU98sb2T0pVYZtu1-Hy-OjioBvX8RdiK8iKilmWOnSOLLAkMZz0lry0xM6SMkwqww13WW4cR4sqR46JK4w1InfSpqXKSrYBi6PxCN9D5IQqVFKyVCByWkT2903KSspkzsoswRa057zXtgYn9zEyfui5keJ5oT0vdOBFC_aaAr8qXI7HSXfDYDZ0ZnLj3dlyoa8GX7RKzoesd5Dpbgu25qOta0m-pcrIAJZCybQFn5vPJIP-YsWMcDyraPx1Mae23lWzpGksk4xxzhX1MIz1U3-raQBD4sNzC3yCle5Fv6d7J4Nvm_CSNDtROcNtweJ0MsOPpD1Ni-0gHn8BnxEK0w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3daxQxEB9qC8UXbf1oz9a6gogve-xuPrZ5PKrXU69HqRbvLSSbCS3Vu3K9A_Gvd5L9wBZFxLeEzedkJjOzmfwC8ErlXtjMlqlwJabcZmVqLPrUGMYMcTVihF08mcjROf8wFW00YbgLU-NDdD_cgmTE_ToI-LXzvwg56T2ZkraZ9gNGOb8HG1xS48EuOusQpGRAJIt3ImNhnjfoPiGY504DtxTTRqDx999ZnbeN2KiFhg_BtuOvg0-u-qul7Vc_7kA7_tcEt-BBY6Mmg5qptmENZ49g86Q5hX8MfHA6Hpwliwtckb07v3QJ8d9FREdKusD1JLja3yhVP9p08wTOh-8-H43S5vWFtBLkQ6WsyD16T_5XlhlOVkvpKqKmowyTynDDfVEaz7FCVSLHzFtTGVF6WeVOFY49hfXZfIa7kHihrMocywUipy3k8NDkzFGm8JUsMuxBvyW9rhpo8vBCxlfduiiBFjrQQkda9OBNV-G6RuX4c9HXcS27cmZxFYLZSqG_TI61yj5N2fio0KMe7LeLrRs5vqHGyP2VQsm8By-7zySB4VjFzHC-qsuEw2JOfe3UTNJ1VkjGOOeKZhiX-m-j1bSAMfHsXyu8gM3Tt0M9fj_5uAf3yawTdSTcPqwvFyt8TqbT0h5E4fgJf9sJiw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=proceeding&rft.title=International+journal+of+rheumatic+diseases&rft.atitle=APLAR+rheumatoid+arthritis+treatment+recommendations&rft.au=Lau%2C+Chak+Sing&rft.au=Chia%2C+Faith&rft.au=Harrison%2C+Andrew&rft.au=Hsieh%2C+Tsu-Yi&rft.date=2015-09-01&rft.eissn=1756-185X&rft.volume=18&rft.issue=7&rft.spage=685&rft.epage=713&rft_id=info:doi/10.1111%2F1756-185X.12754&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-1841&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-1841&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-1841&client=summon |